Deep Track Capital, LP 13F holdings, Q2 2026
Holdings as of June 30, 2026 · filings on SEC EDGAR · this is the latest filing on record
Deep Track Capital, LP disclosed 66 US equity positions worth $6.8bn in its Q2 2026 13F filing. The largest position was GH at 7.5% of the reported book, followed by IMVT and GPCR. Against the Q1 2026 filing, it opened 11 new positions, added to 21 and reduced 10 among the top 50 holdings.
What did Deep Track Capital, LP own in Q2 2026? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2026 |
|---|---|---|---|---|---|---|---|
| 1 | GH GUARDANT HEALTH INC | Healthcare | 7.5% | $509.1m | 3,393,312 | 2% | added |
| 2 | IMVT IMMUNOVANT INC | Healthcare | 5.3% | $359.9m | 9,341,151 | -19% | reduced |
| 3 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 3.7% | $254.4m | 4,740,072 | 11% | added |
| 4 | PCVX VAXCYTE INC | Healthcare | 3.7% | $250.0m | 4,300,000 | 0% | held |
| 5 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 3.7% | $248.3m | 825,000 | – | new |
| 6 | MANE VERADERMICS INC | Healthcare | 3.6% | $245.9m | 2,000,000 | 300% | added |
| 7 | TARS TARSUS PHARMACEUTICALS INC | Healthcare | 3.4% | $230.8m | 3,666,768 | 2% | added |
| 8 | NUVALENT INC | 3.2% | $220.2m | 1,783,322 | 30% | added | |
| 9 | ALKS ALKERMES PLC | Healthcare | 3.1% | $209.6m | 4,000,000 | 11% | added |
| 10 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 2.8% | $193.3m | 19,686,282 | 0% | held |
| 11 | BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 2.8% | $189.3m | 3,307,481 | 188% | added |
| 12 | NRIX NURIX THERAPEUTICS INC | Healthcare | 2.8% | $187.7m | 7,736,455 | 22% | added |
| 13 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 2.7% | $183.3m | 1,926,000 | -5% | reduced |
| 14 | ALMS ALUMIS INC | Healthcare | 2.6% | $178.6m | 6,348,558 | -6% | reduced |
| 15 | IONS IONIS PHARMACEUTICALS INC | Healthcare | 2.6% | $174.4m | 2,200,000 | 13% | added |
| 16 | CMPS COMPASS PATHWAYS PLC | Healthcare | 2.5% | $172.1m | 12,161,496 | 0% | held |
| 17 | VERA VERA THERAPEUTICS INC | Healthcare | 2.5% | $171.6m | 4,000,000 | -3% | reduced |
| 18 | AXSM AXSOME THERAPEUTICS INC. | Healthcare | 2.5% | $171.3m | 700,000 | -36% | reduced |
| 19 | GMAB GENMAB A/S | Healthcare | 2.3% | $155.2m | 5,650,000 | 54% | added |
| 20 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 2.0% | $136.3m | 6,999,025 | 9% | added |
| 21 | HEMAB THERAPEUTICS HLDGS INC | 1.9% | $132.3m | 3,602,093 | – | new | |
| 22 | TNGX TANGO THERAPEUTICS INC | Healthcare | 1.9% | $131.3m | 4,200,000 | 53% | added |
| 23 | DFTX DEFINIUM THERAPEUTICS INC | Healthcare | 1.9% | $129.4m | 2,750,000 | -8% | reduced |
| 24 | GRAL GRAIL INC | Healthcare | 1.8% | $125.3m | 1,834,944 | 7% | added |
| 25 | BCAX BICARA THERAPEUTICS INC | Healthcare | 1.8% | $121.7m | 4,100,000 | 1% | added |
| 26 | MAZE MAZE THERAPEUTICS INC | Healthcare | 1.6% | $111.4m | 3,732,569 | 7% | added |
| 27 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 1.6% | $109.4m | 2,939,151 | 129% | added |
| 28 | LB PHARMACEUTICALS INC | 1.6% | $108.8m | 3,352,804 | 0% | held | |
| 29 | MBX MBX BIOSCIENCES INC | Healthcare | 1.4% | $95.6m | 1,732,569 | -37% | reduced |
| 30 | GHRS GH RESEARCH PLC | Healthcare | 1.3% | $89.6m | 3,333,334 | – | new |
| 31 | COGT COGENT BIOSCIENCES INC | Healthcare | 1.1% | $77.4m | 2,000,000 | 100% | added |
| 32 | ATAI ATAIBECKLEY INC | 1.1% | $76.0m | 14,417,442 | 20% | added | |
| 33 | UTHR UNITED THERAPEUTICS CORP DEL | Healthcare | 1.0% | $67.0m | 123,616 | – | new |
| 34 | AVTX AVALO THERAPEUTICS INC | Healthcare | 1.0% | $66.7m | 3,610,000 | – | new |
| 35 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 1.0% | $66.0m | 3,592,740 | 158% | added |
| 36 | CYTK CYTOKINETICS INC | Healthcare | 0.9% | $59.6m | 700,000 | -49% | reduced |
| 37 | ALT ALTIMMUNE INC | Healthcare | 0.9% | $58.5m | 19,250,000 | – | new |
| 38 | PSNL PERSONALIS INC | Healthcare | 0.8% | $53.6m | 4,000,000 | 33% | added |
| 39 | ACRS ACLARIS THERAPEUTICS INC | Healthcare | 0.7% | $49.4m | 9,345,000 | 0% | held |
| 40 | CRMD CORMEDIX INC | 0.7% | $49.3m | 6,274,076 | 0% | held | |
| 41 | WGS GENEDX HOLDINGS CORP | Healthcare | 0.7% | $48.1m | 700,000 | – | new |
| 42 | HROW HARROW INC | 0.6% | $41.2m | 969,000 | – | new | |
| 43 | CRVS CORVUS PHARMACEUTICALS INC | Healthcare | 0.5% | $37.2m | 2,491,939 | 0% | held |
| 44 | SLDB SOLID BIOSCIENCES INC | Healthcare | 0.5% | $35.6m | 3,565,062 | 0% | held |
| 45 | BEAM BEAM THERAPEUTICS INC | Healthcare | 0.5% | $34.3m | 1,000,000 | 22% | added |
| 46 | DYN DYNE THERAPEUTICS INC | Healthcare | 0.5% | $33.3m | 1,500,000 | -25% | reduced |
| 47 | IMMX IMMIX BIOPHARMA INC | 0.4% | $28.6m | 2,775,000 | – | new | |
| 48 | XFOR X4 PHARMACEUTICALS INC | 0.4% | $27.5m | 5,878,757 | -7% | reduced | |
| 49 | STTK SHATTUCK LABS INC | Healthcare | 0.4% | $25.7m | 3,706,734 | – | new |
| 50 | MNKD MANNKIND CORP | Healthcare | 0.4% | $25.6m | 6,000,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.